Kim-Tien, Ng

Dynamic and results-driven professional with a Ph.D. in Molecular Virology and Evolutionary Biology, recognized for pioneering advancements in viral detection and quantification. I developed and patented a novel assay for rhinovirus quantification, significantly improving disease prognosis assessments and antiviral treatment monitoring. My research delineated the evolutionary history of EV-D68, providing critical insights during unprecedented outbreaks in the U.S.

I have received multiple prestigious awards, including recognition at the 64th Meeting of Nobel Laureates in Physiology and Medicine for Young Scientist (Lindau, Germany) and the 21st CROI Young Investigator Award (Boston, USA). As a Research Associate at Duke-NUS Medical School, I designed innovative peptide libraries for disease outbreak response, and at the National University of Singapore, I optimized SARS-CoV-2 isolation protocols and enhanced detection tools.

With nearly three years of experience as a Scientific Officer in a diagnostic cancer company, I successfully scaled robotic process automation to improve operational efficiency and contributed to achieving College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) accreditations. Currently, as a Program Manager at Xenolis Pte Ltd, I lead cutting-edge projects that utilize six-letter ExSELEX technology to develop XenoAptamer-based innovative diagnostic tools and therapeutics, driving our mission to address global health challenges through strategic planning and collaborative research initiatives.